


Name	Rajat Kumar	
Current Position	Professor, Faculty of Medicine, University of Toronto. Staff Physician and Hematologist, Allogeneic BMT at Princess Margaret Cancer Centre. Head, Malignant Hematology, at Princess Margaret and UHN.	
Country	Canada	
Major Field	Blood and Marrow Transplantation, AML, Aplastic Anemia, MDS, Graft Failure.	

Educational Background

MBBS (1976), MD Medicine (1981) Delhi, India

MRCP (UK) 1989

FRCP and FRCP (Edin) 2001

FRCPC 2008

MSc Health Economics, Policy and Management, LSE, London UK-2012

Professional Experience

Clinical Hematology Training at Guy's Hospital, London UK (1988-1990)

Clinical Hematologist, Armed Forces India: 1990-2003. Set up a BMT centre in Delhi.

Professor of Hematology, All India Institute of Medical Sciences, New Delhi, India; 2003-2008. Set up a BMT centre.

Professor and Hematologist at University of Manitoba and CancerCare Manitoba, Winnipeg, Canada. 2008-2017.

Professor and Hematologist at Princess Margaret Cancer Centre, Toronto, Canada. Working in Allogeneic BMT. 2018-date.

Other Experience and Professional Memberships

Member: ASH, TCT, CTTC, ISHBT.

Main Scientific Publications

1. Salas MQ, Atenafu EG, Bascom O, Wilson L, Lam W, Law AD, Pasic I, Kim DDH, Michelis FV, Al-Shaibani Z, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Alibhai SMH, **Kumar R**. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Jan 1;56(1):60-69.
2. Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W, Law AD, Michelis FV, Thyagu S, Kim D DH, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, **Kumar R**. Efficacy and cost analysis

- of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2021 Oct 1;56(10):2471-2476.
3. Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, Kim DDH, Viswabdya A, Lipton JH, Mattsson J, **Kumar R**. Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. *Eur J Haematol*. 2019 Nov 1;103(5):483-490.
 4. **Kumar R**, Bonfim C, George B. Hematopoietic cell transplantation for aplastic anemia. *Curr Opin Hematol*. 2017; 24: 509-514.
 5. **Kumar R**, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, et al. Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. *Biol Blood Marrow Transplant*. 2016;22(5):932-40.
 6. **Kumar R**, Naithani R, Mishra P, Mahapatra M, Seth T, Dolai TK, et al. Allogeneic hematopoietic SCT performed in non-HEPA filter rooms: initial experience from a single center in India. *Bone Marrow Transplant* 2009; 43(2): 115-119.
-